Navigation Links
Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk
Date:5/6/2013

Minneapolis, MN, May 6, 2013 For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation. Aggressive warfarin anticoagulation is accompanied by significant annual risk of bleeding, while inadequate anticoagulation of a mechanical artificial valve has been associated with high risk of clotting problems that can cause strokes.

A newer generation mechanical heart valve, manufactured by On-X Life Technologies, Austin, TX, has several design features that make it more efficient and less likely to clot. The FDA is allowing a randomized trial to be conducted to determine whether it is safe and effective to treat patients with an On-X mechanical aortic valve with less aggressive anticoagulation than has previously been recommended by the American Heart Association and American College of Cardiology.

In an interim report to be presented at the 93rd AATS Annual Meeting in Minneapolis on May 6, 2013, John D. Puskas, MD, Professor and Associate Chief of the Division of Cardiothoracic Surgery, Emory University School of Medicine, Athens, GA, and his co-investigators show that lower dose anticoagulation therapy, combined with low-dose aspirin, resulted in a reduction of 55 to 60% of the incidence of adverse bleeding events without significant increases in stroke, transient ischemic attack or total neurological events when used in conjunction with the On-X mechanical aortic valve.

As part of the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT), a control group of patients received standard treatment of warfarin administered to maintain a target range of the International Normalized Ratio (INR) of 2.0-3.0. The second treatment group received low-dose warfarin, targeting an INR of 1.5-2.0.

From June 2006 until October 2009, 375 Aortic Valve Replacement (AVR) patients were randomized into control (190) and treatment (185) groups three months after surgery. All patients had received standard therapy for the first 3 months including aspirin 81 mg daily. Mean age was 55.8 years in the control group and 54.1 years in the treatment group. Approximately 80% of the patients were male and 93% were in sinus rhythm before valve replacement. Patients were followed for an average of 3.82 years.

Dr. Puskas concludes that "Anticoagulation may be safely reduced in AVR patients after implantation of this approved bileaflet mechanical prosthesis. In combination with low-dose aspirin, this therapy resulted in significantly lower risk of bleeding than customary aggressive anticoagulation, without significant increase in clots or strokes."


'/>"/>

Contact: Nicole Baritot
press@aats.org
978-299-4520
American Association for Thoracic Surgery
Source:Eurekalert

Related medicine news :

1. Low-Dose Pill Linked to Pain During Orgasm, Study Finds
2. Resistance to low-dose aspirin therapy extremely rare
3. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
4. Low-dose CT screening may benefit individuals at increased risk for lung cancer
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. CWRU School of Medicine researchers discover new target for personalized cancer therapy
7. Women's Excellence in Menopause Now Offering Treatment Options for Decreased Sex Drive near Rochester Hills, Michigan; Natural Therapy Available via Bioidentical Hormones
8. TherapySites and the AAMFT are Offering an Educational Webinar, "4 Online Marketing Trends You Can't Afford To Ignore"
9. North American Seminars Introduces Vestibular Rehabilitation - Examination and Treatment, a New Physical Therapy Online Continuing Education Course
10. Clarifying the effect of stem cell therapy on cancer
11. Get Rid of Varicose Veins in Time for Summer with Shaft Medical San Diego’s Micro Needle Sclerotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... MedPro Waste Disposal, LLC (MedPro) is proud to ... offers its mail back service for an all-inclusive rate. MedPro Disposal President, Dan Hansen, ... service to all of the clients in the country who are looking for an ...
(Date:5/2/2016)... ... May 02, 2016 , ... Further establishing itself as ... that the new WHIMZEES Variety Value Boxes were selected from over 1,000 entrants as ... Award. , WHIMZEES natural dental chews for dogs are a favorite product among ...
(Date:5/2/2016)... CA (PRWEB) , ... May 02, 2016 , ... Dr. ... linking dental health and cognitive decline. According to the research, which was published in ... some degree of cognitive decline, and about 5.4 million Americans have Alzheimer’s disease. The ...
(Date:5/2/2016)... Rafael, CA (PRWEB) , ... May 02, 2016 , ... The 2016 World Ultimate & ... Nike Ultimate Camp at Manhattan College, made the cut. The WUGC is being held in ... National Teams won the gold in the men’s division, another gold in the women’s masters ...
(Date:5/2/2016)... ... 2016 , ... According to an American Psychological Association article, the ... before the age of 18. Of those who survive, many still face effects as ... , In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India , ... the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with policy ...
(Date:5/2/2016)... N.J. , May 2, 2016  Celsion ... development company, today announced data from the first ... escalating clinical trial (the OVATION Study) combining GEN-1, ... care for the treatment of newly-diagnosed patients with ... followed by interval debulking surgery.  In the first ...
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology: